UBS Group set a GBX 4,550 ($61.70) price objective on AstraZeneca (LON:AZN) in a report published on Monday, www.boersen-zeitung.de reports. The firm currently has a neutral rating on the biopharmaceutical company’s stock.
Other equities research analysts have also issued reports about the company. Citigroup set a GBX 6,000 ($81.37) price target on AstraZeneca and gave the stock a buy rating in a research report on Wednesday, September 13th. Berenberg Bank restated a buy rating and set a GBX 5,500 ($74.59) price target on shares of AstraZeneca in a research report on Monday, September 11th. Deutsche Bank increased their price target on AstraZeneca from GBX 5,300 ($71.87) to GBX 5,600 ($75.94) and gave the stock a buy rating in a research report on Monday, September 11th. Liberum Capital restated a buy rating and set a GBX 4,800 ($65.09) price target on shares of AstraZeneca in a research report on Monday, September 11th. Finally, Societe Generale restated a buy rating on shares of AstraZeneca in a research report on Monday, September 11th. Four research analysts have rated the stock with a sell rating, six have given a hold rating and thirteen have assigned a buy rating to the company. The company has an average rating of Hold and an average target price of GBX 5,200.82 ($70.53).
Shares of AstraZeneca (AZN) opened at GBX 5,136 ($69.65) on Monday. The company has a market capitalization of $65,180.00 and a P/E ratio of 2,481.16. AstraZeneca has a 12-month low of GBX 4,136.50 ($56.10) and a 12-month high of GBX 5,520 ($74.86).
AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on discovery and development of products, which are then manufactured, marketed and sold. The Company focuses on three main therapy areas: Oncology, Cardiovascular & Metabolic Disease (CVMD) and Respiratory, while selectively pursuing therapies in Autoimmunity, Infection and Neuroscience.
Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.